Harrow Health, Inc. (HROW)
Stock Price:
$6.01 USD
0.05 (0.84%)
Updated November 25, 4:00 PM EST - Market closed
Key Info
| Market Cap |
154.73M |
| Revenue (ttm) |
46.88M |
| Net Income (ttm) |
-1.85M |
| Shares Out |
25.75M |
| EPS (ttm) |
-0.07 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 25 |
| Last Price |
$6.01 |
| Previous Close |
$5.96 |
| Change ($) |
0.05 |
| Change (%) |
0.84% |
| Day's Open |
5.95 |
| Day's Range |
5.66 - 6.23 |
| Day's Volume |
121,722 |
| 52-Week Range |
3.33 - 7.92 |
More Stats
| Market Cap |
154.73M |
| Enterprise Value |
145.65M |
| Earnings Date (est) |
Mar 18, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.75M |
| Float |
23.61M |
| EPS (basic) |
-0.07 |
| EPS (diluted) |
-0.07 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.33M |
| Short Ratio |
9.02 |
| Short % of Float |
5.62% |
| Beta |
0.95 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3.30 |
| PB Ratio |
6.42 |
| Revenue |
46.88M |
| Operating Income |
-1.32M |
| Net Income |
-1.85M |
| Free Cash Flow |
-541,000 |
| Net Cash |
9.08M |
| Net Cash / Share |
0.35 |
| Gross Margin |
73.41% |
| Operating Margin |
-2.82% |
| Profit Margin |
-3.90% |
| FCF Margin |
-1.15% |
| ROA |
-1.00% |
| ROE |
-8.09% |
| ROIC |
0.50% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$12.50*
(107.99% upside)
Low
12.0
Current: $6.01
High
13.0
Target: 12.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 51.17 | 41.37 | 26.77 | 19.94 | 9.72 | 1.66 | 0.01 | 0.10 | - | - |
| Revenue Growth | 23.67% | 54.52% | 34.26% | 105.25% | 485.3% | 16500% | -90% | - | - | - |
| Gross Profit | 34.42 | 24.85 | 13.27 | 10.11 | 4.51 | 0.57 | 0.01 | 0.10 | - | - |
| Operating Income | -4.80 | -5.22 | -12.16 | -15.88 | -14.82 | -10.15 | -7.69 | -4.18 | -0.94 | -2.50 |
| Net Income | 0.17 | 14.63 | -11.99 | -19.09 | -15.90 | -10.12 | -7.64 | -5.38 | -0.95 | -2.53 |
| Shares Outstanding | 25.32 | 21.92 | 20.03 | 12.74 | 9.58 | 9.13 | 8.66 | 4.49 | 0.40 | 0.39 |
| Earnings Per Share | 0.01 | 0.61 | -0.60 | -1.50 | -1.66 | -1.11 | -0.88 | -1.24 | -2.65 | -6.40 |
| EPS Growth | -98.36% | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow | 0.95 | 0.69 | -8.80 | -11.22 | -11.14 | -7.06 | -4.44 | -1.90 | -0.29 | -2.30 |
| Capital Expenditures | -1.47 | -1.77 | -0.77 | -6.89 | -1.00 | -0.17 | -0.02 | -0.02 | - | - |
| Free Cash Flow | -0.52 | -1.08 | -9.58 | -18.10 | -12.14 | -7.23 | -4.46 | -1.92 | -0.29 | -2.30 |
| Cash & Equivalents | 30.15 | 28.26 | 4.22 | 9.05 | 2.84 | 8.36 | 15.63 | 10.04 | 0.15 | 0.29 |
| Total Debt | 20.99 | 15.25 | 15.33 | 13.69 | 8.36 | 0.04 | - | - | 1.43 | 1.06 |
| Net Cash / Debt | 9.16 | 13.01 | -11.11 | -4.63 | -5.52 | 8.32 | 15.63 | 10.04 | -1.28 | -0.76 |
| Assets | 59.09 | 49.45 | 23.92 | 27.25 | 14.13 | 10.24 | 15.76 | 10.71 | 0.16 | 0.35 |
| Liabilities | 31.67 | 24.70 | 21.30 | 20.82 | 15.52 | 2.09 | 0.65 | 0.71 | 1.86 | 1.39 |
| Book Value | 27.71 | 24.75 | 2.62 | 6.43 | -1.39 | 8.15 | 15.11 | 10.00 | -1.70 | -1.04 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Harrow Health, Inc. |
| Country |
United States |
| Employees |
133 |
| CEO |
Mark L. Baum |
Stock Information
| Ticker Symbol |
HROW |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: HROW |
Description
Harrow Health, together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie's disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.